Influenza virus vaccine (Fluad) - Seqirus

Drug Profile

Influenza virus vaccine (Fluad) - Seqirus

Alternative Names: Chiromas; Fluad; Fluad Pediatric; Gripguard; Influpozzi Adiuvato; MF59-adjuvanted seasonal influenza vaccine (Fluad) - Seqirus; Trivalent Influenza Vaccine (Fluad)- Seqirus

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Vaccines
  • Developer Novartis Vaccines; Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 Aug 2017 Launched for Influenza virus infections (In the elderly, Prevention) in United Kingdom (IM)
  • 22 Aug 2017 Registered for Influenza virus infections (In the elderly, Prevention) in United Kingdom (IM)
  • 29 Aug 2016 Influenza virus vaccine (Fluad) licensed to PaxVax in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top